Catalyst Capital Advisors LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 19.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 56,500 shares of the life sciences company’s stock after selling 13,500 shares during the period. Illumina comprises about 0.6% of Catalyst Capital Advisors LLC’s portfolio, making the stock its 22nd biggest position. Catalyst Capital Advisors LLC’s holdings in Illumina were worth $16,946,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Lindbrook Capital LLC purchased a new stake in shares of Illumina in the fourth quarter valued at about $205,000. First Trust Advisors LP lifted its holdings in shares of Illumina by 7.1% in the fourth quarter. First Trust Advisors LP now owns 508,393 shares of the life sciences company’s stock valued at $152,482,000 after purchasing an additional 33,707 shares in the last quarter. Greenleaf Trust lifted its holdings in shares of Illumina by 1.6% in the fourth quarter. Greenleaf Trust now owns 6,856 shares of the life sciences company’s stock valued at $2,056,000 after purchasing an additional 107 shares in the last quarter. Eaton Vance Management lifted its holdings in shares of Illumina by 66.4% in the fourth quarter. Eaton Vance Management now owns 96,497 shares of the life sciences company’s stock valued at $28,942,000 after purchasing an additional 38,508 shares in the last quarter. Finally, Barings LLC lifted its holdings in shares of Illumina by 43.6% in the fourth quarter. Barings LLC now owns 5,038 shares of the life sciences company’s stock valued at $1,511,000 after purchasing an additional 1,530 shares in the last quarter. 90.32% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently weighed in on ILMN. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a research report on Wednesday, February 13th. Morgan Stanley cut their price objective on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research report on Monday, January 7th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research report on Monday, December 31st. Deutsche Bank lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective for the company. in a research report on Friday, January 25th. Finally, Bank of America reissued a “buy” rating and issued a $355.00 price objective on shares of Illumina in a research report on Wednesday, January 30th. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $346.40.
Shares of ILMN stock opened at $302.24 on Thursday. The firm has a market capitalization of $44.43 billion, a PE ratio of 52.84, a PEG ratio of 2.16 and a beta of 1.20. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a twelve month low of $221.49 and a twelve month high of $372.61.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The firm had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. Illumina’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.44 earnings per share. On average, research analysts predict that Illumina, Inc. will post 6.52 EPS for the current year.
In other news, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction on Wednesday, December 26th. The shares were sold at an average price of $273.87, for a total value of $903,771.00. Following the completion of the transaction, the director now directly owns 339,879 shares in the company, valued at $93,082,661.73. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 124 shares of the company’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $294.71, for a total transaction of $36,544.04. Following the completion of the transaction, the senior vice president now owns 7,003 shares of the company’s stock, valued at $2,063,854.13. The disclosure for this sale can be found here. Insiders sold 40,507 shares of company stock valued at $12,366,915 over the last 90 days. Insiders own 0.54% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Macon Daily and is owned by of Macon Daily. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://macondaily.com/2019/02/21/illumina-inc-ilmn-shares-sold-by-catalyst-capital-advisors-llc.html.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Featured Story: Why do companies issue stock splits?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.